SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity
Authors:
- 6 December 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 555, 216029
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LY23H160016)
- National Natural Science Foundation of China (32070952)
- National Natural Science Foundation of China (81873418)
This publication has 37 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- The tyrosine phosphatase Shp2 (PTPN11) in cancerCancer and Metastasis Reviews, 2008
- Integrating signals from RTKs to ERK/MAPKOncogene, 2007
- A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras ActivationJournal of Biological Chemistry, 2005
- Phosphorylation Regulates KSR1 Stability, ERK Activation, and Cell ProliferationJournal of Biological Chemistry, 2004
- Structural Analysis of Autoinhibition in the Ras Activator Son of SevenlessCell, 2004
- Shp2, an SH2-containing Protein-tyrosine Phosphatase, Positively Regulates Receptor Tyrosine Kinase Signaling by Dephosphorylating and Inactivating the Inhibitor SproutyJournal of Biological Chemistry, 2004
- Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor SignalingMolecular and Cellular Biology, 2003
- EFFICIENT DESIGNS FOR STUDYING SYNERGISTIC DRUG COMBINATIONSLife Sciences, 1997